Search results
Results from the WOW.Com Content Network
In September, Gilead revealed the results of an interim analysis from a second Phase 3 trial investigating the use of the company’s twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir.
However, Gilead has faced its own set of inquiries and legal settlements related to patent gaming — most recently a $40 million settlement for slowing the release of a life-saving HIV treatment ...
Robert Charles Gallo (/ ˈ ɡ ɑː l oʊ /; born March 23, 1937) is an American biomedical researcher.He is best known for his role in establishing the human immunodeficiency virus (HIV) as the infectious agent responsible for acquired immune deficiency syndrome (AIDS) and in the development of the HIV blood test, and he has been a major contributor to subsequent HIV research.
First quarter sales of Gilead's HIV drugs rose to $4.1 billion from $3.6 billion a year earlier. ... Gilead said it expects to have manufactured enough of the drug to treat more than 140,000 ...
In 2019, Gilead Sciences challenged the validity of patents granted to the United States after 2015 for using the drug combination for HIV PrEP and post-exposure prophylaxis (PEP). [ 41 ] [ 42 ] [ 43 ] In July 2024, The Biden administration appealed the jury finding that ruled in favor of Gilead Sciences verdict that the U.S. government's ...
Britain's GlaxoSmithKline will receive $1.25 billion from Gilead Sciences as part of a settlement between its HIV medicines unit and the U.S.-based drugmaker, ending a long-drawn patent dispute.
Already approved as a treatment for multi-drug resistant HIV—costing approximately $42,250 for the first year in the U.S.—lenacapavir has also shown strong efficacy in preventing HIV infection during recent clinical trials. Gilead is actively seeking regulatory approvals for its preventive use worldwide. [56]
For premium support please call: 800-290-4726 more ways to reach us